Emu Oil

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: skin inflammation pain

Research Overview

Across the studies reviewed here, emu oil has been studied most often as a topical adjunct in inflammatory or skin-related contexts, but the depth and quality of evidence varies substantially by indication. One line of literature is formulation-focused: emu oil is discussed as an oil phase in topical nanoemulgel systems intended to improve delivery of hydrophobic anti-inflammatory drugs, largely as a mechanistic/pharmaceutics rationale rather than as direct clinical efficacy evidence for emu oil itself. The most clinically developed area in these studies is supportive care in oncology—specifically radiodermatitis—where emu oil has been evaluated alongside other nonsteroidal topical agents in systematic reviews and guideline development. A smaller clinical signal appears in a randomized, double-blind, placebo-controlled trial of a multi-ingredient topical gel (H-100: nicardipine + superoxide dismutase + emu oil) for acute-phase Peyronie’s disease.

The strongest evidence in this set supports not using emu oil for radiodermatitis outside research settings: both the guideline and the underpinning systematic review/meta-analysis conclude emu oil is equivalent or less effective than standard care and the guideline panel explicitly suggested against it. In contrast, the Peyronie’s disease trial reports statistically significant improvements in curvature, pain, and stretched penile length with H-100 and acceptable tolerability; however, because emu oil is only one component of a combination product, these results do not isolate emu oil’s independent effect. The nanoemulgel review suggests plausible synergistic or permeation-enhancing roles for emu oil in topical delivery systems, but this is primarily inferential and does not constitute high-certainty clinical evidence of benefit.

Key gaps include the need for well-controlled, adequately powered clinical trials that test emu oil as a single active ingredient (or factorial designs that can attribute effects within combination products), with standardized formulations, dosing, and clinically meaningful endpoints. For radiodermatitis specifically, current evidence trends negative, so further research would need strong justification and rigorous design to clarify whether any subpopulation, formulation, or timing could be beneficial. For other inflammatory dermatoses and musculoskeletal conditions, the studies provide rationale but little direct clinical evidence; translational work linking formulation advantages (e.g., nanoemulgels) to patient outcomes, along with robust safety characterization (including dermatitis/sensitization risk), remains a priority.

1. What conditions has Emu Oil been studied for?

  • Radiation-induced skin injury (radiodermatitis) in people receiving radiation therapy for cancer (systematic review/meta-analysis and an evidence-based clinical practice guideline).

  • Acute-phase Peyronie’s disease (topical combination gel “H-100” containing nicardipine, superoxide dismutase, and emu oil) in a randomized, double-blind, placebo-controlled trial.

  • Aromatase inhibitor–induced musculoskeletal symptoms (AIMSS) in breast cancer patients (Cochrane review of systemic therapies includes an emu oil study among heterogeneous interventions; evidence rated low/very low certainty overall).

  • Wound healing / skin tissue engineering (preclinical biomaterials work: emu oil incorporated into electrospun nanofibrous scaffolds to support stem-cell adhesion/proliferation and epidermal differentiation markers).

  • Skin penetration enhancement / topical delivery (mechanistic study using IR microscopy to track emu oil penetration through human skin; and a review describing emu oil as an oil phase in anti-inflammatory nanoemulgels for topical delivery).

2. Does it work in treating those conditions? Summarize the evidence.

  • Radiodermatitis: Evidence does not support benefit.

    • A guideline using GRADE methodology suggested against emu oil for radiodermatitis management.

    • A systematic review/meta-analysis found aloe vera and emu oil were equivalent or less effective than standard care for radiodermatitis outcomes.

  • Acute Peyronie’s disease (H-100 gel that includes emu oil): One small RCT suggests possible benefit, but emu oil is part of a multi-ingredient product.

    • In a prospective randomized double-blind placebo-controlled study (n=22), H-100 showed statistically significant improvements at 6 months in stretched penile length, curvature, and pain; placebo showed minimal change. This supports the combination gel as “possibly effective,” but the study does not isolate emu oil’s independent effect.

  • AIMSS (joint/musculoskeletal symptoms from aromatase inhibitors): Evidence is inconclusive and very uncertain.

    • A Cochrane review (17 RCTs, 2034 participants; low/very low certainty) lists an emu oil study among treatment trials; overall, the authors conclude evidence for safe and effective systemic therapies is minimal and inconclusive. The study does not provide effect sizes for emu oil specifically.

  • Wound healing / skin bioengineering: Promising preclinical signals, not clinical proof.

    • Electrospun scaffolds containing emu oil improved stem-cell adhesion/proliferation and showed cytoprotective (free-radical scavenging) effects, with upregulation of epidermal differentiation markers (keratin 10, filaggrin, involucrin). This is laboratory/preclinical evidence, not direct evidence that topical emu oil heals wounds in humans.

  • Skin penetration enhancement / topical delivery: Mechanistic support, not direct clinical efficacy.

    • An IR microscopy study tracked emu oil penetration through human skin layers, supporting a permeation/penetration-enhancing property.

    • A review on nanoemulgels describes emu oil as an oil phase with anti-inflammatory properties that may provide synergy in topical formulations, but this is not direct clinical evidence for emu oil alone.

3. What health benefits does it have?

  • Potential topical anti-inflammatory role (formulation context): A nanoemulgel review describes emu oil as an oil phase with anti-inflammatory properties used in topical delivery systems, potentially contributing to improved therapeutic profiles when combined with active drugs. This is suggestive rather than definitive clinical proof.

  • Skin permeation enhancement: A mechanistic study using IR microscopy supports that emu oil can penetrate human skin layers, consistent with a penetration-enhancing effect (relevant to topical delivery of other agents).

  • Antioxidant/cytoprotective properties (preclinical): In electrospun scaffold experiments, emu oil contributed free-radical scavenging activity and cytoprotection, and improved stem-cell adhesion/proliferation.

  • Composition consistent with emollient/barrier effects (preclinical characterization): GC/MS and HPLC characterization in the scaffold study found emu oil was mainly fatty acids and carotenoids, which may plausibly support skin-conditioning effects; however, clinical outcomes were not tested in that study.

4. Does it have any downsides or side effects?

  • Lack of efficacy in radiodermatitis: In cancer radiotherapy skin care, emu oil was found equivalent or less effective than standard care in a systematic review, and a guideline suggested against its use. The main “downside” here is opportunity cost (using something that does not help when better-supported options exist, such as topical steroids and dressings per the review).

  • Skin reactions (in combination product): In the Peyronie’s disease H-100 trial, treatment was well tolerated; a self-limited rash occurred in 3 patients. Because H-100 contains multiple ingredients, the rash cannot be attributed to emu oil alone from this study.

  • Product/formulation variability and evidence gaps: The studies imply emu oil is used in diverse formulations (topical oils, combination gels, biomaterial scaffolds). Clinical effects and safety may vary by formulation, dose, purity, and contaminants, but these factors are not resolved in the studies reviewed here.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

No pharmacogenomic (gene–supplement interaction) evidence is provided in the studies for emu oil.

  • No specific genetic variants are identified that predict benefit, non-response, or adverse effects from emu oil.

  • Given the limited and mixed clinical evidence (notably negative/neutral findings in radiodermatitis) and the frequent use of emu oil as part of multi-ingredient formulations, any pharmacogenomic claims would be speculative without targeted studies.

References

  1. An Overview of Nanoemulgels for Bioavailability Enhancement in Inflammatory Conditions via Topical Delivery.
    Diwya Kumar Lal, Bhavna Kumar, Abdulaziz S Saeedan, Mohd Nazam Ansari (2023) - Pharmaceutics
  2. ONS Guidelines™ for Cancer Treatment-Related Radiodermatitis.
    Tracy Gosselin, Pamela K Ginex, Chelsea Backler, Susan D Bruce, Andrea Hutton, Carol M Marquez, Lisa A McGee, Anne Marie Shaftic, Lauren V Suarez, Kerri A Moriarty, Christine Maloney, Mark Vrabel, Rebecca L Morgan (2020) - Oncology nursing forum
  3. Radiodermatitis in Patients With Cancer: Systematic Review and Meta-Analysis.
    Pamela K Ginex, Chelsea Backler, Elizabeth Croson, Lindsey N Horrell, Kerri A Moriarty, Christine Maloney, Mark Vrabel, Rebecca L Morgan (2020) - Oncology nursing forum
  4. Topical treatment for acute phase Peyronie's disease utilizing a new gel, H-100: a randomized, prospective, placebo-controlled pilot study.
    J Twidwell, L Levine (2016) - International journal of impotence research
  5. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
    Kate E Roberts, India T Adsett, Kirsty Rickett, Sophie M Conroy, Mark D Chatfield, Natasha E Woodward (2022) - The Cochrane database of systematic reviews
  6. Cytoprotection, proliferation and epidermal differentiation of adipose tissue-derived stem cells on emu oil based electrospun nanofibrous mat.
    Younes Pilehvar-Soltanahmadi, Mohammad Nouri, Mikaël M Martino, Amir Fattahi, Effat Alizadeh, Masoud Darabi, Mohammad Rahmati-Yamchi, Nosratollah Zarghami (2017) - Experimental cell research
  7. Elucidation of penetration enhancement mechanism of Emu oil using FTIR microspectroscopy at EMIRA laboratory of SESAME synchrotron.
    Randa S H Mansour, Alsayed A Sallam, Imad I Hamdan, Enam A Khalil, Ibraheem Yousef (2017) - Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy
  8. A cannabinoid Hairy-Tale: Hair loss or hair gain?
    Aditya K Gupta, Mesbah Talukder (2022) - Journal of cosmetic dermatology
  9. Amelioration of FCA induced arthritis on topical application of curcumin in combination with emu oil.
    Manish Kumar Jeengar, Shweta Shrivastava, S Chandra Mouli Veeravalli, V G M Naidu, Ramakrishna Sistla (2016) - Nutrition (Burbank, Los Angeles County, Calif.)
  10. Emu Oil: a novel therapeutic for disorders of the gastrointestinal tract?
    Suzanne M Abimosleh, Cuong D Tran, Gordon S Howarth (2012) - Journal of gastroenterology and hepatology
  11. Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss.
    Rethi Raghu Nadhanan, Suzanne M Abimosleh, Yu-Wen Su, Michaela A Scherer, Gordon S Howarth, Cory J Xian (2012) - American journal of physiology. Endocrinology and metabolism
  12. Improvement of bioavailability and anti-inflammatory potential of curcumin in combination with emu oil.
    Manish Kumar Jeengar, Shweta Shrivastava, Kala Nair, Sreenivasa Reddy Singareddy, Uday Kumar Putcha, M V N Kumar Talluri, V G M Naidu, Ramakrishna Sistla (2014) - Inflammation
  13. Review on emu products for use as complementary and alternative medicine.
    Manish Kumar Jeengar, P Sravan Kumar, Dinesh Thummuri, Shweta Shrivastava, Lalita Guntuku, Ramakrishna Sistla, V G M Naidu (2015) - Nutrition (Burbank, Los Angeles County, Calif.)
  14. Emu Oil Improves Clinical Indicators of Disease in a Mouse Model of Colitis-Associated Colorectal Cancer.
    Lauren C Chartier, Gordon S Howarth, Ian C Lawrance, Debbie Trinder, Scott J Barker, Suzanne Mashtoub (2018) - Digestive diseases and sciences
  15. Emu Oil Combined with Lyprinol™ Reduces Small Intestinal Damage in a Rat Model of Chemotherapy-Induced Mucositis.
    Suzanne Mashtoub, Lorrinne S Lampton, Georgina L Eden, Ker Y Cheah, Kerry A Lymn, Juliana E Bajic, Gordon S Howarth (2016) - Nutrition and cancer
  16. Effects of Topical Emu Oil on Burn Wounds in the Skin of Balb/c Mice.
    Mohammad Afshar, Reza Ghaderi, Mahmoud Zardast, Parvin Delshad (2016) - Dermatology research and practice
  17. Emu oil and grape seed extract reduce tumour burden and disease parameters in murine colitis-associated colorectal cancer.
    Lauren C Chartier, Gordon S Howarth, Debbie Trinder, Suzanne Mashtoub (2021) - Carcinogenesis
  18. Emu Oil Attenuates Disease Severity and Results in Fewer Large Colonic Tumors in a Mouse Model of Colitis-Associated Colorectal Cancer.
    Suzanne Mashtoub, Lauren C Chartier, Debbie Trinder, Ian C Lawrance, Gordon S Howarth (2022) - Nutrition and cancer
  19. The emu oil emulsified in egg lecithin and butylated hydroxytoluene enhanced the proliferation, stemness gene expression, and in vitro wound healing of adipose-derived stem cells.
    Khatereh Saei Arezoumand, Effat Alizadeh, Mohammad Esmaeillou, Maryam Ghasemi, Shahriar Alipour, Younes Pilehvar-Soltanahmadi, Nosratollah Zarghami (2018) - In vitro cellular & developmental biology. Animal
  20. Combined Nutraceuticals: A Novel Approach to Colitis-Associated Colorectal Cancer?
    Lauren C Chartier, Gordon S Howarth, Suzanne Mashtoub (2019) - Nutrition and cancer


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!